SCHEMBL4257502

SCHEMBL4257502

CC(C)(C)/C(=C\C(=O)O)c1ccc(C(=C2CCCCC2)c2ccc(O)cc2)c(Cl)c1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 6/20 0.38
ESR2 Q92731 5/20 0.38
PGR P06401 1/20 0.34
CHRM2 P08172 1/20 0.34
ADORA3 P0DMS8 1/20 0.34
AR P10275 1/20 0.34
CHRM1 P11229 1/20 0.34
SLC6A2 P23975 1/20 0.34
SLC6A3 Q01959 1/20 0.34
DPP4 P27487 2/20 0.32
NR1H4 Q96RI1 1/20 0.31
RXRA P19793 1/20 0.31
ESRRB O95718 1/20 0.31
ESRRG P62508 1/20 0.31
OPRM1 P35372 1/20 0.30
OPRD1 P41143 1/20 0.30
OPRK1 P41145 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4258861 0.87 ESR1 (0.38) ESR1ESR2PGRCHRM2ADORA3
SCHEMBL4257434 0.84 ESR1 (0.47) ESR1ESR2PGRCHRM2ADORA3
SCHEMBL4258950 0.84 ESR1 (0.47) ESR1ESR2PGRCHRM2ADORA3
SCHEMBL4259418 0.83 ESR1 (0.45) ESR1ESR2PGRCHRM2ADORA3
SCHEMBL4253218 0.83 ESR1 (0.42) ESR1ESR2PGRCHRM2ADORA3
SCHEMBL4256094 0.80 ESR1 (0.40) ESR1ESR2PGRCHRM2ADORA3
SCHEMBL4257511 0.80 ESR1 (0.40) ESR1ESR2PGRCHRM2ADORA3
SCHEMBL3468201 0.77 ESR1 (0.52) ESR1ESR2PGRDPP4
SCHEMBL3468206 0.77 ESR1 (0.52) ESR1ESR2PGRDPP4
SCHEMBL4262517 0.76 ESR1 (0.39) ESR1ESR2PGRCHRM2ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7569601-B2 Cycloalkylidene compounds as modulators of estrogen receptor SMITHKLINE BEECHAM CORPORATION (US) 2009-08-04 US disclosed
US-20070213348-A1 Chemical Compounds BRITTON JONATHAN E 2007-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213348-A1 Chemical Compounds GPER1, ESR2, ESR1 ESR1 3/4885ESR2 2/4885PGR 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.